A Phase I/II Study of Pembrolizumab and Vorinostat in Patients With Immune Therapy Naïve and Immune Therapy Pretreated Stage IV NSCLC
Phase of Trial: Phase I/II
Latest Information Update: 18 Jul 2017
At a glance
- Drugs Pembrolizumab (Primary) ; Vorinostat (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 12 Jul 2017 Planned End Date changed from 1 Nov 2018 to 1 Nov 2019.
- 10 Jun 2017 Biomarkers information updated
- 18 May 2017 Planned End Date changed from 1 Nov 2017 to 1 Nov 2018.